The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.

Yassar M HashimSuwanna VangveravongNarendra V SankpalPratibha S BinderJingxia LiuS Peter GoedegebuureRobert H MachDirk SpitzerWilliam G Hawkins

Published in: Journal of experimental & clinical cancer research : CR (2017)

We believe that the strong sensitizing capacity of SW IV-134 in combination with clinically relevant doses of gemcitabine represents a promising treatment option that warrants clinical evaluation.

Keyphrases

clinical evaluation
locally advanced
transcription factor
binding protein
squamous cell carcinoma
radiation therapy